{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:39:16Z","timestamp":1787017156156,"version":"build-2736575974"},"reference-count":30,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,6,7]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe factors associated with initiating antipsychotics and patterns of persistence to antipsychotic therapy in a large cohort of adults with intellectual and developmental disabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Population-based cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Ontario, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults with intellectual and developmental disabilities (IDD) in Ontario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>We used multivariable logistic regression to investigate patient characteristics associated with antipsychotic initiation. Patient characteristics studied included sociodemographic characteristics, measures of clinical comorbidity and health service use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 39\u2009244 individuals eligible for this study, 6924 (17.6%) initiated an antipsychotic over the accrual window, of whom 1863 (26.9%) had no psychiatric diagnosis in the prior 2 years. A number of factors were significantly associated with antipsychotic initiation, including male gender, residence in a group home, prior use of benzodiazepines, antidepressants or cognitive enhancers, a recent emergency department visit or mental health hospitalisation and a visit to a psychiatrist or family physician in the prior 90 days. In a secondary analysis, the association between antipsychotic initiation and age, prior diagnosis of diabetes or myocardial infarction and polypharmacy differed slightly on the basis of whether an individual had a previously diagnosed psychiatric disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Factors associated with the initiation of an antipsychotic differ according to the presence of a psychiatric diagnosis. Given the long duration of antipsychotic use in this population, future research is needed to understand the appropriateness of antipsychotic initiation among adults with IDD and the safety implications of long-term use of these products.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-028125","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T05:35:12Z","timestamp":1564551312000},"page":"e028125","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study"],"prefix":"10.1136","volume":"9","author":[{"given":"Tara","family":"Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Khuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Vigod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Cobigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Lunsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"2024052012323257000_9.7.e028125.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2004.03.004"},{"key":"2024052012323257000_9.7.e028125.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2013.11.011"},{"key":"2024052012323257000_9.7.e028125.3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2215-0366(16)30191-2","article-title":"Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review","volume":"4","author":"Sheehan","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"2024052012323257000_9.7.e028125.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.2000.00307.x"},{"key":"2024052012323257000_9.7.e028125.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-012-1617-6"},{"key":"2024052012323257000_9.7.e028125.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2012.01631.x"},{"key":"2024052012323257000_9.7.e028125.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4326"},{"key":"2024052012323257000_9.7.e028125.8","doi-asserted-by":"crossref","unstructured":"Lunsky Y , Khuu W , Tadrous M , et al . Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. Can J Psychiatry 2018;63.doi:10.1177\/0706743717727240","DOI":"10.1177\/0706743717727240"},{"key":"2024052012323257000_9.7.e028125.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60072-0"},{"key":"2024052012323257000_9.7.e028125.10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1192\/bjpo.bp.116.002691","article-title":"Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs","volume":"2","author":"Vigod","year":"2016","journal-title":"BJPsych Open"},{"key":"2024052012323257000_9.7.e028125.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017406","article-title":"Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study","volume":"7","author":"Sheehan","year":"2017","journal-title":"BMJ Open"},{"key":"2024052012323257000_9.7.e028125.12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.141267"},{"key":"2024052012323257000_9.7.e028125.13","doi-asserted-by":"crossref","unstructured":"Lunsky Y , Klein-Geltink JE , Yates EA . Atlas on the primary care of adults with developmental disabilities in Ontario. Institute for Clinical Evaluative Sciences & Centre for Addiction and Mental Health. Toronto: ON, 2013.","DOI":"10.1037\/e506482014-001"},{"key":"2024052012323257000_9.7.e028125.14","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.3.512"},{"key":"2024052012323257000_9.7.e028125.15","first-page":"e18","article-title":"Accuracy of administrative databases in identifying patients with hypertension","volume":"1","author":"Tu","year":"2007","journal-title":"Open Med"},{"key":"2024052012323257000_9.7.e028125.16","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.123839"},{"key":"2024052012323257000_9.7.e028125.17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40801-016-0073-6","article-title":"Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study","volume":"3","author":"Mast","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"2024052012323257000_9.7.e028125.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2298"},{"key":"2024052012323257000_9.7.e028125.19","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.10.1090"},{"key":"2024052012323257000_9.7.e028125.20","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200410000-00004"},{"key":"2024052012323257000_9.7.e028125.21","doi-asserted-by":"publisher","DOI":"10.3109\/00048670903279838"},{"key":"2024052012323257000_9.7.e028125.22","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"2024052012323257000_9.7.e028125.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7497.960"},{"key":"2024052012323257000_9.7.e028125.24","unstructured":"National Core Indicators. What does NCI tell us about adults with intellectual and developmental disabilities who are taking prescribed medications for anxiety, behavior challenges, mood disorders or psychotic disorders? 2012."},{"key":"2024052012323257000_9.7.e028125.25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ridd.2011.08.003","article-title":"Antipsychotic medication prescription patterns in adults with developmental disabilities who have experienced psychiatric crisis","volume":"33","author":"Lunsky","year":"2012","journal-title":"Res Dev Disabil"},{"key":"2024052012323257000_9.7.e028125.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013116","article-title":"Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice","volume":"6","author":"Paton","year":"2016","journal-title":"BMJ Open"},{"key":"2024052012323257000_9.7.e028125.27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/jir.12391","article-title":"Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland","volume":"61","author":"O\u2019Dwyer","year":"2017","journal-title":"J Intellect Disabil Res"},{"key":"2024052012323257000_9.7.e028125.28","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.110.085670"},{"key":"2024052012323257000_9.7.e028125.29","doi-asserted-by":"publisher","DOI":"10.1177\/1744629513495261"},{"key":"2024052012323257000_9.7.e028125.30","unstructured":"National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. 2015 https:\/\/www.nice.org.uk\/guidance\/ng11 (accessed 24 May 2018)."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-028125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T15:44:53Z","timestamp":1716219893000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-028125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,30]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bmjopen-2018-028125"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-028125","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}